Grifols (GIFLF) Total Current Liabilities (2009 - 2025)
Grifols' (GIFLF) quarterly Total Current Liabilities came in at $2.4 billion in Q4 2025, up 2.01% on a YoY basis from $2.3 billion in Q4 2024, and up 2.01% quarter-over-quarter from $2.3 billion in Q4 2024.
Analysis
Grifols (GIFLF) Total Current Liabilities (2009 - 2025) Analysis & Trends
Grifols (GIFLF) has reported Total Current Liabilities for 17 consecutive years, with $2.4 billion the latest figure, recorded in Q4 2025.
- For the quarter ending Q4 2025, Total Current Liabilities rose 2.01% year-over-year to $2.4 billion; the trailing twelve-month figure through Dec 2025 stood at $2.4 billion (up 2.01% YoY), and the FY2025 full-year result was $2.3 billion, up 4753.38% from the prior year.
- Total Current Liabilities climbed to $2.4 billion in Q4 2025 per GIFLF's latest filing, from $2.3 billion in the prior quarter.
- Across five years, Total Current Liabilities topped out at $4.0 billion in Q4 2021 and bottomed at $2.1 billion in Q4 2022.
- Historically, Total Current Liabilities has averaged $2.6 billion across 5 years, with a median of $2.4 billion in 2025.
- The sharpest annual moves came in 2021 and 2022: Total Current Liabilities soared 149.68% in 2021, then slumped 48.17% in 2022.
- Over 5 years, Total Current Liabilities stood at $4.0 billion in 2021, then plunged by 48.17% to $2.1 billion in 2022, then increased by 21.45% to $2.5 billion in 2023, then decreased by 7.92% to $2.3 billion in 2024, then climbed by 2.01% to $2.4 billion in 2025.
- According to Business Quant data, Total Current Liabilities over the past three periods registered $2.4 billion, $2.3 billion, and $2.5 billion for Q4 2025, Q4 2024, and Q4 2023 respectively.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Current Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Amgen | 203.97 Bn | 189.99 Bn | 7.24 Bn | 25.50 Bn |
| 2 | Gilead Sciences | 178.74 Bn | 175.56 Bn | 6.22 Bn | 11.02 Bn |
| 3 | Vertex Pharmaceuticals | 130.73 Bn | 122.88 Bn | 2.84 Bn | 3.94 Bn |
| 4 | Regeneron Pharmaceuticals | 80.42 Bn | 72.42 Bn | 3.93 Bn | 5.53 Bn |
| 5 | Argenx Se | 60.40 Bn | 55.21 Bn | 1.37 Bn | 1.58 Bn |
| 6 | Moderna | 57.65 Bn | 52.52 Bn | 52.00 Mn | 2.53 Bn |
| 7 | Alnylam Pharmaceuticals | 33.37 Bn | 30.07 Bn | 992.69 Mn | 1.51 Bn |
| 8 | Biogen | 32.15 Bn | 30.86 Bn | 1.96 Bn | 3.92 Bn |
| 9 | Roivant Sciences | 29.58 Bn | 29.58 Bn | 1.16 Mn | 283.60 Mn |
| 10 | Grifols | 7.54 Bn | 9.09 Bn | 3.33 Bn | 2.35 Bn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Dec 31, 2025 | 2.35 Bn |
| Dec 31, 2024 | 2.30 Bn |
| Dec 31, 2023 | 2.50 Bn |
| Dec 31, 2022 | 2.06 Bn |
| Dec 31, 2021 | 3.97 Bn |
| Dec 31, 2020 | 1.59 Bn |
| Sep 30, 2020 | 1.45 Bn |
| Mar 31, 2020 | 1.47 Bn |
| Dec 31, 2019 | 1.51 Bn |
| Sep 30, 2019 | 1.55 Bn |
| Dec 31, 2018 | 91.37 Mn |
| Sep 30, 2018 | 1.26 Bn |
| Jun 30, 2018 | 96.90 Mn |
| Mar 31, 2018 | 1.49 Bn |
| Dec 31, 2017 | 1.15 Bn |
| Jun 30, 2017 | 85.29 Mn |
| Dec 31, 2016 | 1.16 Bn |
| Sep 30, 2016 | 97.13 Mn |
| Jun 30, 2016 | 132.34 Mn |
| Dec 31, 2015 | 1.15 Bn |